Insulin co-formulations: Discontinuation
Some insulin products are being discontinued.
21 October 2025 | Apidra (10 ml inj) added
The supplier of Apidra has decided to stop supplying the 10 ml injection. The 3 ml injection and disposable pen will remain available.
Affected products
The following products are being discontinued:
| Brand | Presentation | Chemical | Pharmacode | Supply ends | Funding ends |
|---|---|---|---|---|---|
| PenMix 30 | Inj human with neutral insulin 100 u per ml, 3 ml | Isophane insulin, insulin neutral | 785733 | October 2025 | remaining stock expires April 2026 |
| Apidra | Inj 100 u per ml, 10 ml | Insulin glulisine | 2317109 | April 2026 | to be confirmed |
| NovoMix 30 FlexPen | Inj human with neutral insulin 100 u per ml, 3 ml | Isophane insulin, insulin neutral | 2404303 | Mid-2026 | to be confirmed |
People who use these products
There are funded alternatives. You can continue to access funded insulin treatment. You will need to talk to your prescriber as soon as possible to discuss the best options for your clinical situation.
For health care professionals
There are a number of other fully funded insulin products that may be suitable alternatives for your patients.
PenMix 30
The remain stock of this product expires in April 2026. The NZSSD has issued guidance to support clinicians with the discontinuation of this product.
NZSSD Guidance: Discontinuation of PenMix30 and PenMix 50 and Mixtard 30 [PDF, 140 KB]
Apidra
Only the 10 ml inj is being discontinued. Stock of the 3 ml injection and disposable pen will remain available. Fewer than 30 people are currently getting the 10 ml injection vial size.
Schedule listings for insulin glulisine(external link)
NovoMix 30 FlexPen
Stock is expected to run out by mid-2026. We funded Ryzodeg which may be a suitable alternative to NovoMix 30.
Ryzodeg (biphasic insulin degludec + insulin aspart) monograph | NZ Formulary(external link)
More information
We encourage health care professionals to discuss a safe transition to an alternative funded product based on your patient’s individual needs.
Schedule listings for short-acting insulin preparations(external link)
Schedule listings for intermediate-acting insulin preparations(external link)
Insulin information in the NZ Formulary(external link)
Background
The insulin products on this page are supplied by a range of companies. These companies are discontinuing supply of some of their products that aren't used much or have been superseded by other insulin products.
All information about insulin discontinuations have been put on one page to allow health care providers to see the full range of affected products.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)